Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 12Endocrine 12Thoracic 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1NET 1Myeloid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 46Neoplasms 8Carcinoid Tumor 7Neoplasm Metastasis 5Gastro-enteropancreatic neuroendocrine tumor 5Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Serotonin Syndrome 2Sarcoma 2Pheochromocytoma 2Paraganglioma 2Neuroblastoma 2Neoplasms by Site 2Digestive System Neoplasms 2Digestive System Diseases 2Cholangiocarcinoma 2Carcinoma, Islet Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2von Hippel-Lindau Disease 1Vipoma 1

Interventions

tislelizumab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid Carcinoma, Anaplastic × NET × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡